1. Home
  2. FXAC vs VANI Comparison

FXAC vs VANI Comparison

Compare FXAC & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FXAC

FortuneX Acquisition Corporation Ordinary shares

N/A

Current Price

$10.14

Market Cap

128.0M

Sector

Finance

ML Signal

N/A

Logo Vivani Medical Inc. (DE)

VANI

Vivani Medical Inc. (DE)

HOLD

Current Price

$1.03

Market Cap

111.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FXAC
VANI
Founded
2026
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
128.0M
111.0M
IPO Year
2026
2014

Fundamental Metrics

Financial Performance
Metric
FXAC
VANI
Price
$10.14
$1.03
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $3.83
AVG Volume (30 Days)
79.9K
★ 230.4K
Earning Date
N/A
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $4,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$10.00
$0.80
52 Week High
$10.22
$1.66

Technical Indicators

Market Signals
Indicator
FXAC
VANI
Relative Strength Index (RSI) 58.81 40.30
Support Level $10.09 $0.92
Resistance Level N/A $1.21
Average True Range (ATR) 0.02 0.10
MACD 0.00 -0.00
Stochastic Oscillator 53.85 57.49

Price Performance

Historical Comparison
FXAC
VANI

About FXAC FortuneX Acquisition Corporation Ordinary shares

FortuneX Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.

About VANI Vivani Medical Inc. (DE)

Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.

Share on Social Networks: